An Analysis of Sex Steroid Receptors and p53 in Uterine Smooth Muscle Cell Tumors
子宫平滑肌细胞肿瘤中性类固醇受体和 p53 的分析
基本信息
- 批准号:09671671
- 负责人:
- 金额:$ 1.92万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1997
- 资助国家:日本
- 起止时间:1997 至 1998
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Smooth muscle tumors of the uterus can be divided histologically into benign, malignant, and borderline types. The histological heterogeneity of these smooth muscle tumors suggests that there may be differences in growth potential as well as in growth mechanism among the various types. However, the molecular mechanisms involved in the growth regulation of these tumors are not fully understood. To investigate the cell cycle regulatory machineries involved in the growth mechanism. of smooth muscle tumors, we studied the expression of Ki-67, cyclins E and A, and their catalytic partners, the cyclin-dependent kinases cdk2 and cdc2 using tissue specimens from benign and malignant smooth muscle tumors. These included 20 cases of usual leiomyoma (UL), 18 of cellular leiomyoma (CL), 8 of bizarre leiomyoma (BL), 8 of uncertain malignant potential tumors (UMP.), and 20 of leiomyosarcorna (LMS). The proliferation rate detected by Ki-67 was low in normal myometrium and leiomyomas (UL, CL, and BL), but it was markedly increased in LMS.The expression of the cyclins (E and A), and cdks (cdk2 and cdc2) was also low in normal myometrium and leiomyomas. However, the expression of these factors was markedly increased in LMS.In addition, a survival analysis by Log-rank test revealed that those LMSs with positive staining for cyclin A and with diffusely staining for cyclin E were associated with significantly shorter survival. These results suggest that expression of cyclins and cdks may be involved in the growth control of uterine smooth muscle tumors.
子宫平滑肌肿瘤在组织学上可分为良性、恶性和交界性三种类型。这些平滑肌肿瘤的组织学异质性表明,可能有不同的生长潜力,以及在不同类型之间的生长机制。然而,参与这些肿瘤生长调节的分子机制尚未完全了解。探讨细胞周期调控机制在细胞生长机制中的作用。在平滑肌肿瘤中,我们研究了Ki-67,细胞周期蛋白E和A,以及它们的催化伙伴,细胞周期蛋白依赖性激酶cdk 2和cdc 2的表达,使用组织标本从良性和恶性平滑肌肿瘤。其中普通型平滑肌瘤(UL)20例,富于细胞型平滑肌瘤(CL)18例,奇异型平滑肌瘤(BL)8例,恶性潜能不明型平滑肌瘤(UMP)8例,平滑肌角(LMS)20例。Ki-67在正常子宫肌层和平滑肌瘤(UL、CL和BL)中的增殖率较低,而在LMS中增殖率明显增高,cyclins(E和A)和cdks(cdk 2和cdc 2)在正常子宫肌层和平滑肌瘤中的表达也较低。然而,这些因子的表达显着增加LMS。此外,生存分析的对数秩检验显示,那些LMS与阳性染色的细胞周期蛋白A和弥漫染色的细胞周期蛋白E与显着较短的生存。这些结果表明,细胞周期蛋白和cdks的表达可能参与子宫平滑肌肿瘤的生长控制。
项目成果
期刊论文数量(16)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A Horiuchi, et al: "Reduced expression of Calponin hl in leiomyosarcoma of the uterus" Laboratory Investigation. 78,7. 839-846 (1998)
A Horiuchi 等人:“子宫平滑肌肉瘤中钙调蛋白 hl 的表达降低”实验室调查。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ya-Li ZHAI et al: "Expression of cyclins and cyclin-dependent kinase in smooth muscle tumors of the uterus" International J Cancer. in press.
ZHAI ZHAI 等人:“子宫平滑肌肿瘤中细胞周期蛋白和细胞周期蛋白依赖性激酶的表达”国际癌症杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
A Horiuchi,et al: "Reduced expression of Calponin h1 in leiomyosarcoma of the uterus" Laboratory Investigation. 78,7. 839-846 (1998)
A Horiuchi 等人:“子宫平滑肌肉瘤中钙调蛋白 h1 的表达减少”实验室调查。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ya-Li ZHAI et al: "Expression of steroid receptors,Ki-67,and p53 in uterine leiomyosarcomas" International J Gynecol Pathol. 18. 20-28 (1999)
ZHAI ZHAI 等:“子宫平滑肌肉瘤中类固醇受体、Ki-67 和 p53 的表达”国际妇科病理杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Zhai YL,Nikaido T,Shiozawa T,Orii A,Fujii S: "Expression of cyclins and cyclin-dependent kinase in smooth muscle tumors of the uterus" International, J Cancer. (in press).
Zhai YL,Nikaido T,Shiozawa T,Orii A,Fujii S:“子宫平滑肌肿瘤中细胞周期蛋白和细胞周期蛋白依赖性激酶的表达”国际,癌症杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHIMIZU Motohiko其他文献
SHIMIZU Motohiko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Deciphering the functional role of recurrent PPP2R1A mutations on endometrial metastasis
破译PPP2R1A复发突变对子宫内膜转移的功能作用
- 批准号:
10601651 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Multicenter study to develop a model for differentiating uterine leiomyoma and sarcomas by deep Learning and anomaly detection
多中心研究通过深度学习和异常检测开发区分子宫肌瘤和肉瘤的模型
- 批准号:
23K14866 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Targeting Macrophages to Treat Soft Tissue Sarcomas
靶向巨噬细胞治疗软组织肉瘤
- 批准号:
10760719 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Platform to develop targeted therapies for aggressive less common gynecological cancers
开发针对侵袭性不太常见妇科癌症的靶向疗法的平台
- 批准号:
10733237 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Development of novel therapeutics for uterine leiomyosarcoma mediated by KIF4A and CDC25
KIF4A 和 CDC25 介导的子宫平滑肌肉瘤新疗法的开发
- 批准号:
23K08797 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS
项目 3:应用液体活检技术检测 LMS 治疗的临床反应和耐药机制
- 批准号:
10493631 - 财政年份:2022
- 资助金额:
$ 1.92万 - 项目类别:
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS
项目 3:应用液体活检技术检测 LMS 治疗的临床反应和耐药机制
- 批准号:
10705742 - 财政年份:2022
- 资助金额:
$ 1.92万 - 项目类别:
PROJECT 2: Understanding the role of TP53 in LMS development
项目 2:了解 TP53 在 LMS 开发中的作用
- 批准号:
10493630 - 财政年份:2022
- 资助金额:
$ 1.92万 - 项目类别:
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment
平滑肌肉瘤 (LMS) 的遗传学和基因组学:增进对癌症生物学和诊断和治疗新方法的了解
- 批准号:
10493627 - 财政年份:2022
- 资助金额:
$ 1.92万 - 项目类别:














{{item.name}}会员




